



Invitation to the presentation of SenzaGen's January-March 2024 interim report

Lund, May 10, 2024

SenzaGen invites journalists, investors and analysts to a livestream presentation on May 15, 2024, at 9:00 CEST at which President and CEO Peter Nählstedt will present the Q1 report 2024.

The conference call, to be held in Swedish, will begin with a presentation, followed by a Q&A session moderated by Carnegie Investment Banks analyst Klas Palin.

The report will be published on May 15, 2024, at 8:30 CEST.

Time: Wednesday May 15, 9:00–10:00 CEST.

Link to the livestream: <https://youtube.com/live/kh3swMMDJPI?feature=share>

The presentation can be watched afterwards at SenzaGen's website: <https://senzagen.com/investors/presentations/>

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About us

SenzaGen is a corporate group that aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.



Attachments

[Invitation to the presentation of SenzaGen's January-March 2024 interim report](#)